鸿富瀚 reported revenue of ¥0.59B for the period ended 2026-06-30, +65.7% year on year. Net income was ¥0.05B, a 8.6% net margin on a 36.0% gross margin. The largest revenue line is 消费电子产品功能性器件 at 56% of the total. Free cash flow for the period was ¥-0.24B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.59B | +65.7% |
| Gross profit | ¥0.21B | — |
| Operating income | ¥0.07B | — |
| Net income | ¥0.05B | +153.3% |
| Gross margin | 36.0% | Net margin 8.6% |
| Revenue Q/Q | +8.8% | — |
| Segment | Revenue | Share |
|---|---|---|
| 消费电子产品功能性器件 | ¥0.33B | 55.7% |
| 散热产品 | ¥0.11B | 18.3% |
| 自动化设备及相关产品 | ¥0.08B | 14.1% |
| 材料及其他 | ¥0.06B | 9.9% |
| 光伏储能产品 | ¥0.01B | 2.0% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.38B | 64.0% |
| R&D | ¥0.04B | 7.3% |
| SG&A | ¥0.07B | 12.7% |
| Tax & other | ¥0.02B | 2.8% |
| Item | Amount |
|---|---|
| Total assets | ¥5.10B |
| Total liabilities | ¥3.15B |
| Shareholders' equity | ¥1.96B |
| Equity / assets | 38.3% |
| Operating cash flow | ¥-0.14B |
| Capital expenditure | ¥0.10B |
| Free cash flow | ¥-0.24B |
| Cash conversion (OCF / net income) | -1411% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
可孚医疗 ・ 戎美股份 ・ 拓新药业 ・ 华润材料 ・ 深城交 ・ 争光股份 ・ 华兰股份 ・ 广立微 ・ 百诚医药 ・ 天益医疗 ・ 金埔园林 ・ 雅创电子
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies